Ipsen S.A. is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines. The firm's primary focus is on specialty care, targeting thr... Ipsen S.A. is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines. The firm's primary focus is on specialty care, targeting three core therapeutic areas: oncology, neuroscience, and rare diseases. With an extensive portfolio, Ipsen offers well-known brands such as Somatuline for neuroendocrine tumors, Cabometyx for oncology, Dysport for movement disorders, and Bylvay for rare diseases. The company maintains an active research pipeline with several candidates in various stages of clinical development across its key areas, including both established treatments and emerging therapies for conditions with significant unmet medical needs. Founded in 1929 and headquartered in France, Ipsen plays a significant role in advancing medical science and improving patient outcomes worldwide. Its presence in major pharmaceutical markets, commitment to innovation, and focus on specialized medicine have made it a noteworthy player in the healthcare sector, with both a robust commercial footprint and a reputation for research excellence.
Pending data availability
Energy Management Data missing for Ipsen
We haven’t collected Energy Management data for Ipsen yet, or the company
hasn’t made it publicly available.